By Virginia Value Investor : Theravance (NASDAQ: THRX ) is probably a familiar name ..... you're not familiar with it, Theravance is a biopharmaceutical company ..... NYSE: GSK ). On June 2nd, Theravance completed a spin separating
tiotropium bromide inhalation spray for the treatment of bronchospasms in patients with chronic obstructive pulmonary disease (COPD). Related tickers: ( GSK +0.6% ) ( THRX -1.4% ) ( NVS +0.7% ) ( AZN +0.1% ) Post your comment!
By Jim Bowie : Typical antibiotic regimes for treating Acute Bacterial Skin and Skin Structure Infections ("ABSSSI") have run about 7 - 14 days and often include twice daily infusions to treat serious infections. These long-winded treatments ultimately support the buildup of resistance as bacteria
Theravance Biopharma (NASDAQ: TBPH ): Q2 EPS of -$1.83. Revenue of $3M. Press Release Post your comment!
Theravance Biopharma ( TBPH +2.6% ) Q2 results : Revenues: $3.0M (+999%); Operating Expenses: $59.4M (+52.3%); Net
By Early Retiree : Yesterday, Theravance (NASDAQ: THRX ) released its Q2 earnings update. Being still in the ..... which was the first without Biopharma (NASDAQ: TBPH ). Theravance has $369 million of cash, which cover its announced
Theravance , Inc. (NASDAQ: THRX ) Q2 2014 Earnings Conference Call August 06, 2014 05:30 PM ET ..... afternoon. At this time I would like to welcome everyone to the Theravance conference call. During the presentation all participants will
Theravance , (NASDAQ: THRX ) declares $0.25/share quarterly dividend . Payable Sept. 18; for shareholders of record Aug. 28; ex-div Aug. 26. Post your comment!
Theravance ( THRX -1.5% ) promotes SVP and CFO Michael W. Aquiar to President and ..... remain Chairman of the Board and will transition to full-time CEO of Theravance Biopharma on August 15, 2014. Post your comment!
Theravance ( THRX -1.5% ) Q2 results : Revenues: $934K (-29.3%); Operating Expenses: $10.7M (+30.5%); Operating Loss